The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

Breast cancer is the most common cancer in the UK but what are the symptoms to look out for, what causes it and how can it be ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

Routine screening for patient-reported outcomes may improve access to supportive care services among long-term metastatic breast cancer survivors.